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Abstract 
Background: The management of non-fermentative gram-negative bloodstream infection (NFGN-BSI) offers numer-
ous challenges. In this study the aim is to analyse a large cohort of patients with NFGN-BSI recruited in the northern 
Italy to describe epidemiology, etiological and susceptibility pattern, therapeutic management and outcome.
Methods: Multicentre retrospective cohort study of patients hospitalised at three large teaching hospitals in north-
ern Italy in a fourth year period.
Results: 355 BSI episodes were analyzed, due to P. aeruginosa (72.7%), A. baumannii (16.6%), and Stenotrophomonas 
maltophilia (10.7%). Overall, 21.4% of isolates were defined as DTR, highest rate among A. baumannii (64.4%). All-cause 
30-day mortality rate was 17.5%. Rates of XDR or DTR A. baumannii isolation were significantly higher in non-surviving 
patients. Independent risk factors for 30-day mortality were: age (HR 1.03, 95%CI 1.00–1.04, p = 0.003), septic shock 
(HR 2.84, 95%CI 1.67–4.82, p < 0.001) and BSI due to Acinetobacter baumannii (HR 2.23, 95%CI 1.27–3.94, p = 0.005).
Conclusion: The overall prevalence of DTR was high in the NFGN BSI cohort analyzied, mainly among Acinetobacter 
baumannii episodes (64.4%). Acinetobacter baumannii is showed to be an independent predictor of mortality. These 
evidences marked the urgent need of new therapeutic options against this pathogen.
Trial registration number: 79/2017/O/OssN. Approved: March14th, 2017.
Keywords: Bloodstream infection, Non-fermentative gram-negative bacteria, Multidrug resistance, Difficult to treat 
resistance, Therapeutic management, 30-Day mortality
© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which 
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or 
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line 
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this 
licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco 
mmons. org/ publi cdoma in/ zero/1. 0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
The management of non-fermentative gram-negative 
bloodstream infection (NFGN-BSI) offers numerous 
challenges. Indeed, there are several clinical and micro-
biological issues that may contribute to its high morbidity 
and mortality. NFGN-BSI is usually diagnosed in people 
with severe underlying conditions, critically ill and/or 
immunocompromised patients [1–3]. Isolates are gener-
ally resistant, or prone to acquire resistance, to first-line 
antibiotics resulting in a high rate of initial inappropriate 
therapy and/or in the use of less effective and more toxic 
drugs. To counteract these findings, antibiotic combina-
tion regimens are frequently employed with controversial 
results in terms of efficacy, toxicity and collateral envi-
ronmental damage [3, 4].
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The knowledge of local epidemiology, etiological distri-
bution in terms of causative agents and antibiotic resist-
ance, therapeutic approach and factors associated with 
poor outcome are useful to guide infection control and 
antimicrobial stewardship policies and to inform clini-
cians regarding the best treatment approach [4].
With this premise, we analysed a large cohort of 
patients with NFGN-BSI recruited in three regions of 
northern Italy to describe the current epidemiology, etio-




Multicentre retrospective cohort study of patients hospi-
talised at three large teaching hospitals in northern Italy: 
(i) Sant’Orsola Malpighi Hospital, Bologna; (ii) City of 
Health and Sciences, Molinette Hospital, Turin; (iii) San 
Martino Hospital, Genoa. The study period was from 
January 1st 2013 to December 31st 2016. Patients were 
identified through the records of the Microbiology Labo-
ratory of each hospital.
Data source was the clinical charts and hospital 
records, reviewed until 90 days after the index blood cul-
tures (BCs). Study variables were collected using a case 
report form. Data accuracy was assessed by a senior 
investigator. In addition, the numbers of patient days per 
year were recorded to assess the incidence of NFGN-BSI 
in the participating hospitals during the study period.
The study was approved by the institutional Ethics 
Committee of coordinating center, Sant’Orsola Malpighi 
Hospital (Comitato Etico di Area Vasta Emilia Cen-
tro—CE-AVEC79/2017/O/OssN). According to local 
rules, due to the retrospective nature of the study, the 
acquisition of consent by the interested parties was not 
envisaged in case of organizational impossibility. The col-
lection of informed consent was obtained in all cases in 
which it was possible to provide adequate information to 
the patients. Patients were aware that samples could be 
used in research and that data could be published. Data 
were collected anonymously.
The antibiotic treatment, both empirical and definitive, 
was selected according to clinical judgment and not dic-
tated by study protocol. As for polymyxin based therapy, 
colistin is the only drug available in Italy.
Participants
All adult (≥ 18  years) patients diagnosed with NFGN-
BSI were included in the study. NFGN-BSI was defined 
as one or more positive BCs obtained from a patient sus-
pected of having infection. Patients were considered only 
once at the time of first episode (index BCs).
Exclusion criteria included: (i) polymicrobial BSI, 
defined as growth of more than one micro-organism, 
excluding potential contaminants (i.e. coagulase-negative 
staphylococci, Corynebacterium spp., Propionibacterium 
spp.); (ii) clinical data not available.
Variables and definitions
The primary outcome was all-cause mortality within 
30  days after index BCs [5]. The predictor variables 
included age and sex. The Charlson comorbidity index 
was used to asses underlying disease [6]. Immunosup-
pression included: neutropenia (neutrophil count < 500/
mm3), solid organ transplantation, hematopoietic stem 
cell transplantation, corticosteroid therapy (at a dos-
age higher then or equivalent to prednisone 16  mg/
day ≥ 15  days), uncontrolled human immunodeficiency 
virus (HIV) infection (< 200 CD4/mm3).
BSI was classified into nosocomial, healthcare-asso-
ciated and community acquired using Friedman’s crite-
ria [7]. Clinical severity at infection onset was assessed 
according to Sequential Organ Failure Assessment 
(SOFA) score and septic shock criteria [8]. BSI sources 
were established according to Centers for Disease Con-
trol and Prevention (CDC) criteria [9]. BSI was consid-
ered as primary in case of unrecognized source. BSI was 
defined as complicated when the infection source was 
not fully removable.
The susceptibility pattern of isolates was classified 
according to Magiorakos et al. criteria [10] as multidrug 
resistance (MDR) as nonsusceptibility to ≥ 1 agent in ≥ 3 
antimicrobial categories; extensive drug resistance (XDR) 
as susceptibility limited to ≤ 2 categories; and pan-drug 
resistance (PDR) as nonsusceptibility to all agents in all 
antimicrobial categories.
In addition, CDC surveillance definitions were used 
to assess susceptibility to carbapenems, extended-spec-
trum cephalosporins (ESC) and fluoroquinolones (FQ) 
(https:// gis. cdc. gov/ grasp/ PSA/ Downl oads/ AR- Pheno 
typeD efini tions. pdf ). Moreover susceptibility to betalac-
tam/betalactamase inhibitors (BL/BLI) and colistin was 
determined according to European Committee for Anti-
microbial Susceptibility Testing (EUCAST) criteria.
The new definition of “difficult to treat resistance” 
(DTR) was also assessed as reported elsewhere [11, 12]. 
Empirical therapy was defined as antibiotics administered 
before the susceptibility report was available. Appropri-
ate empirical therapy was defined as a therapy contained 
at least one in vitro active drug (according to the suscep-
tibility pattern of the isolate) administered within 24  h 
after drawing index BCs. Inappropriate empirical therapy 
was defined as inactive antibiotic administration or a 
delayed antibiotic therapy. Antibiotic treatment adminis-
tered according to susceptibility results was considered as 
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definitive antibiotic therapy. Antibiotic regimens includ-
ing more than one anti-gram-negative agents, irrespec-
tive of their in vitro activity against the BSI isolate, during 
more than 50% of treatment duration were defined as 
“combination regimen”. Antibiotic therapy including at 
least two drugs showing in vitro activity against the BSI 
isolate was labelled as “2-in vitro active combination regi-
men”. Duration of antibiotic treatment was defined as the 
number of consecutive days during which the patient 
received an appropriate antibiotic regimen. Source con-
trol was defined as the removal of the infection source 
within 7 days of index BCs, including the performance of 
non-surgical or surgical procedures to treat an obstruc-
tive focus or abscess at any site including, among others, 
the urinary tract, biliary tract and surgical site, and the 
removal of any device deemed as the source of BSI.
Microbiology
BCs were incubated using the BACTEC FX Automated 
Blood Culture System (Becton Dickinson, Franklin Lakes, 
NJ). All positive BCs were processed with Maldi Bio-
typer MALDI-TOF system (Bruker Daltonics, Bremen, 
Germany) for rapid and reliable species identification of 
microorganisms. Antimicrobial susceptibility testing was 
performed using the Vitek 2 automated system (bioMer-
ieux, Marcy l’Etoile, France) in two hospitals (Bologna 
and Genova) and the MicroScan system in the remain-
ing hospital (Torino). The minimum inhibitory concen-
trations (MICs) were interpreted using EUCAST clinical 
breakpoints for all tested antibiotics.
Statistical analysis
For the descriptive analysis, categorical variables were 
presented as absolute numbers and their relative fre-
quencies. Continuous variables were presented as the 
mean and standard deviation if normally distributed or 
as the median and interquartile range (IQR) if non-nor-
mally distributed.
Univariate and multivariate analysis were used to 
assess risk factors for all-cause 30-day mortality. Categor-
ical variables were compared using χ2 or Fisher exact test 
when appropriate. Continuous variables were compared 
using the Mann–Whitney U-test. Significant and clini-
cally relevant covariates identified in univariate analysis 
were introduced into a multivariable Cox regression sur-
vival model after verifying for proportional hazards and 
collinearity. Significance was considered for p < 0.05. All 
the analysis were performed using SPSS software.
Results
Over the study period, 527 patients were diagnosed 
with NFGN-BSI. Of them, 172 were excluded: 146 
patients had polymicrobial bacteremia, and for the 
remaining 26 patients clinical data were not available. 
Thus, 355 patients (177 from Bologna, 155 from Turin 
and 23 from Genova) were analysed (Fig. 1).
The overall incidence of Pseudomonas aeruginosa BSI 
per 1000 patient days was 0.12, 0.12, 0.17, and 0.23 in 
2013, 2014, 2015 and 2016, respectively. It was similar 
between participating hospitals. The overall incidence 
of Acinetobacter baumannii BSI per 1000 patient days 
was 0.02, 0.03, 0.06, and 0.04 in 2013, 2014, 2015 and 
2016, respectively. It was similar between participating 
hospitals. Data shown in Fig. 2.
Etiological distribution and susceptibility patterns 
are shown in Table  1. Most episodes were due to P. 
aeruginosa (n = 258, 72.7%), followed by A. bauman-
nii (n = 59, 16.6%), and Stenotrophomonas maltophilia 
(n = 38, 10.7%). Overall, 21.4% of isolates were defined 
as DTR with highest rate among A. baumannii (64.4%). 
Susceptibility rates to individual antibiotic categories 
Fig. 1 Flow diagram of study population
Fig. 2 Overall incidence of P. aeruginosa and A. baumannii BSI per 
1000 patient days between 2013 and 2016 years
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are shown in Fig. 3. Both P. aeruginosa and A. bauman-
nii maintained high rate susceptibility to colistin.
The general characteristics of study population are 
shown in Table  2. Overall, 65.6% of patients were male, 
the median age was 67 (IQR 55–79) years, the median 
Charlson index was 5.7 (IQR 3.6–7.4), and 24.5% were 
immunocompromised. Most patients were hospitalized 
at a medical ward at BSI onset (59.2%), and the major-
ity of episodes were hospital acquired (70.1%). Infection 
source was not identified in 183 (51.5%) cases, in the 
remaining cases the most common sources of NFGN-BSI 
were CVC (n = 102) and lower respiratory tract (n = 49).
As shown in Fig.  4, data on empirical and definitive 
antibiotic therapy were available for 266 (75%) and 333 
(94%) patients, respectively. Active therapy was adminis-
tered in 35.2% and 73.8% of empiric and definitive cohort 
patients, respectively. Empiric combination regimens 
were used in 55 (15.5%) patients with a 2-in vitro active 
drugs in 16 (4.5%). Combination regimens were used in 
32.4% of patients in the definitive cohort, 16.3% with 2-in 
vitro active drugs. Empiric and definitive antibiotic regi-
mens according to isolates are shown in Additional file 1: 
Tables S1 and S2.
All-cause 30-day mortality rate was 17.5%. Relapse at 
90 days was observed in 7 patients (2%) within a median 
of 30  days (IQR 17–50) after index BCs. Compared to 
patients who were alive at day 30 (Table 2), non-surviving 
patients exhibited higher age, Charlson index and SOFA 
score, and higher rate of septic shock. Rates of A. bau-
mannii, XDR or DTR isolation were significantly higher 
in non-surviving patients, while the rates of P. aeruginosa 
isolation and empirical active therapy were higher among 
survivors. For definitive therapy, the use of any combi-
nation was associated with higher mortality while that 
of 2-in vitro active combination did not. At multivari-
ate analysis adjusted for DTR, Stenotrophomonas malt-
ophilia BSI, Acinetobacter baumanni BSI, Pseudomonas 
aeruginosa BSI, active empiric therapy, active targeted 
therapy and source control, the independent risk factors 
for all-cause 30-day mortality were: age (odds ratio, OR 
1.03, 95%, confidence interval, CI 1.00–1.04, p = 0.003), 
septic shock (OR 2.84, 95%CI 1.67–4.82, p < 0.001) and 
BSI due to Acinetobacter baumannii (OR 2.23, 95%CI 
1.27–3.94, p = 0.005). Furthermore, risk factors for 
30-day mortality have been estimated separately among 
patients with P. aeruginosa (Additional file 1: Table 3), A. 
baumannii (Additional file 1: Table 4) and S. maltophilia 
BSI (Additional file 1: Table 5).
Discussion
In our large cohort of NFGN-BSI we have found high 
rates of DTR and carbapenem resistance, especially 
among A. baumannii. Empirical active therapy admin-
istration was significantly higher in surviving patients at 
univariate analysis, however it was not confirmed at mul-
tivariate analysis. Combination therapy, also with 2 active 
Table. 1 Causative agents and their susceptibility patterns of monomicrobial NFGN-BSI during 2013–2016 in three tertiary teaching 
hospitals from northern Italy
Resistance categories (MDR, XDR, PDR) were mutually exclusive while antibiotic class resistances (CR) and new definition (DTR) were not
CR carbapenem resistance, DTR difficult-to-treat resistance, MDR multidrug-resistance, PDR pandrug-resistance, XDR extensively drug-resistance
N MDR XDR PDR CR DTR
Pseudomonas aeruginosa 258 15 (5.8) 53 (20.5) / 82 (31.8) 35 (13.6)
Acinetobacter baumannii 59 0 37 (62.7) 1(1.7) 41 (69.7) 38 (64.4)
Stenotrophomonas maltophilia 38 / / / / 2 (5.3)
Fig. 3 Susceptibility rates to individual antibiotic categories for Pseudomonas aeruginosa, Acinetobacter baumannii and Stenotrophomonas 
malptophilia. BL/BLI betalactam/betalactamase inhibitor, ESC extended-spectrum cephalosporin, FQ fluoroquinolone resistance
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Table. 2 Univariate analysis of risk factors for all-cause 30-day mortality
TotalN = 355 (%) SurvivorsN = 293 (%) Non-survivorsN = 62 (%) p
Demographics
Age (years) (median, IQR) 67 (55–79) 67 (54–78) 73 (61–84) 0.016
Male sex 233 (65.6) 194 (66.2) 39 (62.9) 0.66
Comorbidities
Charlson index (median, IQR) 5.7 (3.6–7.4) 5.2 (3.5–7.1) 6.25 (4–9) 0.034
Immunosuppression 87 (24.5) 74 (25.3) 13 (21) 0.52
Ward of admission 0.22
Medical 210 (59.2) 176 (60.1) 34 (54.8)
ICU 80 (22.5) 61 (20.8) 19 (30.6)
Surgical 65 (18.3) 56 (19.1) 9 (14.5)
Site of BSI acquisition 0.078
Community acquired 71 (20.0) 65 (22.2) 6 (9.7)
Healthcare associated 35 (9.9) 27 (9.2) 8 (12.9)
Hospital acquired 249 (70.1) 201 (68.6) 48 (77.4)
CRE carrier at BSI onset 44 (12.1) 35 (11.9) 9 (14.5) 0.462
Clinical severity at BSI onset
SOFA (median, IQR) 3 (2–5) 3 (2–5) 4 (3–6) 0.005
Septic shock 59 (16.6) 38 (13) 21 (33.9) 0.001
Source of BSI
Undefined 183 (51.5) 150 (51.2) 33 (53.2) 0.782
CVC related 102 (28.7) 86 (29.4) 16 (25.8) 0.645
Lower respiratory tract 49 (13.8) 39 (13.3) 10 (16.1) 0.686
Biliary tract 41 (11.5) 34 (11.6) 7 (11.3) 1
Urinary tract 31 (8.7) 27 (9.2) 4 (6.5) 0.624
Intra-abdominal 18 (5.1) 16 (5.5) 2(3.2) 0.551
Complicated BSI 38 (10.7) 27 (12.9) 11 (21.6) 0.125
Etiology 0.009
Pseudomonas aeruginosa 258 (72.7) 222 (75.8) 36 (58.1) 0.005
Acinetobacter baumannii 59 (16.6) 41 (14) 18 (29) 0.005
Stenotrophomonas maltophilia 38 (10.7) 30 (10.2) 8 (12.9) 0.651
Resistance phenotypes* 0.005
MDR 34 (9.6) 22 (8.4) 12 (22.2)
XDR 58 (16.3) 46 (17.5) 12 (22.2)
Antibiotic class resistance*
ECR 95 (26.7) 77 (26.3) 18 (29) 0.752
BL/BLIR 78 (22) 55 (18.8) 23 (37.1) 0.002
CR 124 (34.9) 93 (31.7) 31 (50) 0.008
FQR 144 (40.6) 107 (36.5) 37 (59.7) 0.001
AminoglycosidesR 98 (27.6) 69 (26.4) 29 (51.8)  < 0.001
TMP/SMXR 53 (14.9) 39 (21.9) 14 (29.2) 0.337
COLIR 5 (1.4) 5 (1.7) 0 (0) 0.592
New definition*
DTR 75 (21.1) 52 (17.7) 23 (37.1) 0.001
Therapeutic management
ID consultation 148 (41.7) 119 (40.6) 29 (46.8) 0.397
Source control 131 (36.9) 111 (37.9) 20 (32.3) 0.470
Appropriate empirical therapy 125 (35.2) 111 (38.4) 14 (23.7) 0.037
Combination empirical therapy 55 (15.5) 42 (18.9) 13 (29.5) 0.152
2 In vitro active combination empirical therapy 16 (4.5) 16 (12.8) 0 0.223
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drug, was not associated to improving surviving at multi-
variate analysis. Of note, A. baumannii isolation resulted 
as independent risk factors for mortality at multivariate 
analysis. In our cohort nosocomial infections accounted 
for a large majority of cases (70%), mainly central venous 
catheter (CVC) related and pneumonia, according to 
literature [13, 14]. Therefore, promote and improve 
infection control programs would play a critical role in 
reducing the rates of this kind of nosocomial infections.
The increasing importance of the NFGN bacteria is 
also related to their complex antimicrobial resistance 
profile. In our cohort carbapenem resistance showed 
high prevalence, with 31.8% and 64.4% rates for P. aer-
uginosa and A. baumannii respectively. We have also 
analysed the prevalence of the new definition DTR. 
This definition reflects the use of second-line agents 
with poorer therapeutic index, resulting in a better 
prediction of poor outcome. In our cohort, the over-
all prevalence of DTR was 21.1%. It varied across spe-
cies being highest among A. baumannii BSI with rates 
of 64.4%. This value was much higher than data pre-
sent in literature [11, 15]. Similarly, DTR prevalence 
for P.aeruginosa BSI, accounted for 13.6%, higher than 
the rates showed previously [11, 15]. As expected, in A. 
baumannii strain, CR and DTR rates were comparable.
In our study active therapy did not result statisti-
cally associated with improved outcome as previously 
reported elsewhere. This finding deserves further inves-
tigation. Indeed, the classical way to define if an antimi-
crobial agent is useful to treat an infection is the MIC 
determination of strains. However, MIC determination 
have some concerns: (i) clinical laboratories cannot 
determine MICs with sufficient accuracy owing to the 
assay variation in the MIC test especially when auto-
mated or semi-automated methods are used, (ii) the 
MIC does not represent a concentration directly com-
pared with in  vivo concentration found during treat-
ment; (iii) bacterial growth conditions in  vitro could 
be different from those in  vivo [16]. Also, the in  vitro 
activity of antimicrobial often does not reflect the 
clinical feasibility due to the specific pharmacokinetic/
toxicodynamic profile of the drugs and the source of 
infection [17]. These considerations could explain why 
in our cohort active therapy seems not associated to 
BL/BLIR betalactam/betalactamase inhibitor resistance, BSI bloodstream infection, COLIR colistin resistance, CR carbapenem resistance, CRE carbapenem-resistant 
Enterobacteriaceae, CVC central venous catheter, DTR difficult-to-treat resistance, ECR extended-spectrum cephalosporin resistance, FQR fluoroquinolone resistance, 
ICU intensive care unit, IQR interquartile range, ID Consultation Infectious Disease Consultation, MDR multidrug-resistance, SOFA sequential organ failure assessment, 
TMP/SMXR trimethoprim/sulfamethoxazole resistance, XDR extensively drug-resistance
* Resistance categories were mutually exclusive while antibiotic class resistances and new definition (DTR) were not
Table. 2 (continued)
TotalN = 355 (%) SurvivorsN = 293 (%) Non-survivorsN = 62 (%) p
Appropriate definitive therapy 262 (73.8) 222 (76.8) 40 (67.8) 0.184
Combination definitive therapy 115 (32.4) 89 (32) 26 (47.3) 0.031
2 In vitro active combination definitive therapy 
(with drugs)
58 (16.3) 48 (20.7) 10 (23.8) 0.682
Fig. 4 Antibiotic management of NFGN-BSI
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improving surviving. Similar experiences were previ-
ously reported elsewhere [18].
In our study, A. baumannii was an independent pre-
dictor of mortality. This is line with the characteristics 
of this pathogen that is commonly responsible for severe 
opportunistic nosocomial infections mainly in hospital-
ized immunocompromised patients [1–3]. Additionally, 
the complex antimicrobial resistance profile and the lim-
ited therapeutic arsenal for this strain may explain this 
result. In this scenario, polymyxins remains in  vitro the 
most active agent. However, the in vitro activity of poly-
myxins not reflect the clinical feasibility due to the sub-
optimal pharmacokinetic/toxicodynamic profile of this 
class [17]. In all the study centers the polymyxin used for 
the treatment of A. baumannii BSI was colistin.
Our study has a number of limitations. Although we 
have analysed a large cohort of patients in three differ-
ent centres, the results could be influenced by the epi-
demiology of a restricted area of our country. Also, our 
cohort is from all large tertiary teaching hospital reflect-
ing the complexity and epidemiology of patients man-
aged in similar institutions. The retrospective collection 
of patient and microbiological data could have limited 
integrity and accuracy. However, a senior investigator 
and three young investigators revised all clinical report 
forms (CRFs), and reconciled data reports and missing 
data with the medical records before including informa-
tion in the database.
Conclusions
To conclude, the overall prevalence of DTR was high in 
our NFGN BSI cohort, mainly among Acinetobacter bau-
mannii episodes. Furthermore, Acinetobacter baumannii 
is showed to be an independent predictor of mortality. 
These evidences marked the urgent need of new thera-
peutic options against this pathogen.
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